Erectile Dysfunction Market - Global Outlook and Forecast 2018-2023

  • ID: 4461299
  • Report
  • Region: Global
  • 182 pages
  • Arizton
OFF
until Dec 31st 2018
1 of 5

FEATURED COMPANIES

  • Apricus Biosciences
  • Bonro Medical
  • Coloplast A/S
  • Endo International plc
  • Pfizer
  • Premedon
  • MORE
This market research report on the erectile dysfunction market offers analysis on market size and forecast, market share, industry trends, growth drivers, and vendor analysis. The study also includes insights on segmentation by therapy type (drug therapies and device therapies) and geography (APAC, Europe, Latin America, MEA, and North America).

Erectile Dysfunction Market - Overview

Increasing disease awareness, growing patient willingness to seek medical assistance for disease management, and the increasing presence of favorable guidelines are driving the growth of the erectile dysfunction market. The three most popular erectile dysfunction drugs that are available in the market are ED oral drugs, Viagra, Cialis, and Levitra. The global erectile dysfunction market is also witnessing a rising demand for low-cost generic drugs, especially in the APAC countries such as Indian and China.

The US and Europe are the main revenue contributors in the global erectile dysfunction market. The growing number of chronic medical conditions such as diabetes, hypertension, dyslipidemia, and coronary heart disease across the globe is also increasing the number of erectile dysfunction patients and boosting the demand for therapeutics in the global market. The increasing investments in R&D for the development of new drugs and clinical trials will augment the growth of the erectile dysfunction market.

The growing awareness of male sexual health conditions and the increasing healthcare spending for sexual wellness, especially in the APAC region will propel the development of the erectile dysfunction market. The introduction of innovative drug therapy will have a positive impact on the growth of the erectile dysfunction market. The erectile dysfunction market is expected to generate revenue of $4.25 billion during the forecast period.

Erectile Dysfunction Market - Dynamics

Increase in strategic agreements and consolidations among the leading vendors to expand their services or product portfolios is likely to contribute to the growth of the global erectile dysfunction market. Mergers and acquisitions will allow players to gain competitive advantage with a wide product portfolio and vast geographical reach, thereby driving the growth and profitability of vendors in the erectile dysfunction market. These strategic consolidations and mergers will help prominent companies to expand their businesses in emerging markets and widen their distribution networks to attract a large consumer base. For instance, a licensing agreement between A. Menarini Asia-Pacific and Mitsubishi Tanabe Pharma was signed to commercialize and promote avanafil in China, Hong Kong, Taiwan, Macao, the Philippines, Singapore, Indonesia, Malaysia, Thailand, and Vietnam.

Erectile Dysfunction Market Segmentation

This market research report includes a detailed segmentation of the market by therapy and geography.

Erectile Dysfunction Market - By Therapy Type

Drugs therapy type to dominate the erectile dysfunction market during the forecast period.

The erectile dysfunction market by therapy type is classified into drugs and devices. The drugs therapy segment dominated the erectile dysfunction market, accounting for close to 89% of the total market share in 2017 and is expected to generate revenue of about $3,487.41 million during the forecast period. Preferability for needle-free penile injection kits and increase in disease awareness will fuel the growth of this drug segment in the erectile dysfunction market. The market for other drug therapy types, topical agents, intraurethral suppositories, and intracavernosal injections is expected to grow at a moderate pace over the next few years. The erectile dysfunction market will also observe a negative growth due to the patent expiration of generic versions of key oral drugs Viagra, Cialis, and Levitra during the forecast period.

Erectile Dysfunction Market - By Geography

North America to occupy the largest market share in the erectile dysfunction market during the forecast period.

The geographical segment in the erectile dysfunction market is divided into APAC, Europe, Latin America, MEA, and North America. North America dominated the global erectile dysfunction market, occupying more than 43% of the total market share in 2017 and is expected to generate the revenue of $1,832.82 million by 2023. Factors such as better access to ED treatments and reimbursement coverage for high post penile implant surgeries is fueling the growth of the erectile dysfunction market in North America.

The US accounts for more than 90% of the total market share in the erectile dysfunction market in North America. The high uptake and access to both prescription and OTC devices in North America is attributing the revenue of the erectile dysfunction market in this region. Moreover, increasing penile implantation surgical procedures, growing e-commerce sales of penile erection devices, and rising preference for advanced non-invasive devices will have a positive impact on the growth of the erectile dysfunction market in North America.

Key Countries Profiled

The key countries profiled in the report are:
  • US
  • Canada
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Japan
  • India
  • China
  • Australia
  • Brazil
  • Mexico
Key Vendor Analysis

The erectile dysfunction market is oligopolistic, as a limited number of major players occupies the predominant market share. A minority of the market share has occupied by a surfeit of specialty and generic drug companies. The strategic initiatives adopted by the leading and other prominent companies will intensify the competition in the erectile dysfunction market during the forecast period. The leading companies are focusing on leveraging their strengths to diversify their product portfolios and increase their global market presence. The entry of new players and the introduction of innovative therapeutics will increase the level of competition in the global erectile dysfunction market during the forecast period.

The major vendors in the global market are:
  • Bayer AG
  • Eli Lilly and Company
  • VIVUS Inc.
  • Pfizer
  • Boston Scientific Corp.
  • Coloplast A/S
Other prominent vendors include: Apricus Biosciences, Inc, Endo International plc, Futura Medical, Premedon, Teva Pharmaceutical Industries Limited (Teva), Zephyr Surgical Implants (ZSI), Augusta Medical Systems LLC (Augusta Medical), Post-T-Vac Medical, Bonro Medical, Cristalia Produtos Quimicos Farmaceuticos Ltd, and SK Chemicals.

Key market insights include:

1. The analysis of erectile dysfunction market provides market size and growth rate for the forecast period 2018-2023.
2. It offers comprehensive insights on current industry trends, trend forecast, and growth drivers about the erectile dysfunction market.
3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.
4. It offers a complete overview of market segments and the regional outlook for erectile dysfunction market.
5. The report offers a detailed overview of the vendor landscape, competitive analysis, and key market strategies to gain competitive advantage.

Report Sanapshot

According to the latest industry analysis, the size of the global erectile dysfunction market is expected to reach $4.25 billion by 2023. The market research report provides in-depth market analysis and segmental analysis of the global erectile dysfunction market by product, distribution channel, material, and geography.

The global erectile dysfunction market is driven by the wide availability of treatment options oral therapies and newly emergent low-intensity extra-corporeal shockwave therapy. The introduction of other conventional therapies such as oral, topical, penile injectables, and vacuum constriction devices will also create opportunities for vendors in the global erectile dysfunction market.

Base Year: 2017
Forecast Year: 2018-2023

The study considers the present scenario of the global erectile dysfunction market and its market dynamics for the period 2018-2023. The study covers a detailed overview of various market growth enablers, restraints, and trends. It covers both the demand and supply sides of the market. The study also profiles and analyzes the top six leading companies and 12 other prominent companies operating in the market.

Major Vendors in the Erectile Dysfunction Market
  • Bayer AG
  • - Key Financial Highlights
  • - Strength Assessment
  • - Strategy Assessment
  • - Opportunity Assessment
  • Eli Lilly and Company
  • VIVUS Inc.
  • Pfizer
  • Boston Scientific Corp.
  • Coloplast A/S
Prominent Players in the Erectile Dysfunction Market
  • Apricus Biosciences Inc.
  • - Strength Assessment
  • - Strategy Assessment
  • - Opportunity Assessment
  • Endo International plc
  • Futura Medical
  • Premedon
  • Teva Pharmaceutical Industries Limited (Teva)
  • Zephyr Surgical Implants (ZSI)
  • Augusta Medical Systems LLC (Augusta Medical)
  • Post-T-Vac Medical
  • Bonro Medical
  • Cristalia Produtos Quimicos Farmaceuticos Ltd.
  • SK Chemicals
Market Segmentation by Therapy Type

ED Drugs
  • Oral Therapies
  • Topical Therapies
  • Intrauretheral suppositories & Penile injection therapies
ED Devices
  • Vacuum erection devices
  • Penile Implants
  • Others
Market Segmentation by Geography

North America
  • US
  • Canada
Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
APAC
  • Japan
  • India
  • China
  • Australia
Latin America
  • Brazil
  • Mexico
MEA
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Apricus Biosciences
  • Bonro Medical
  • Coloplast A/S
  • Endo International plc
  • Pfizer
  • Premedon
  • MORE
1 Research Methodology

2 Research Objectives

3 Research Process

4 Report Coverage
4.1 Market Definition
4.2 Base Year
4.3 Scope of Study
4.3.1 Market Segmentation by Therapy Type
4.3.2 Market Segmentation by Geography

5 Report Assumptions & Caveats
5.1 Currency Conversion rate
5.2 Market Derivation

6 Market at a Glance

7 Introduction
7.1 Overview OF Penile Erection and Erectile Dysfunction
7.2 Signs and Symptoms
7.3 Classification
7.3.1 Psychogenic ED
7.3.2 Neurogenic ED
7.3.3 Vasculogenic ED
7.4 Etiology of ED
7.5 Epidemiology

8 Disease Diagnosis and Treatment Guidelines
8.1 Diagnosis
8.2 Initial Assessment of Medical and Sexual History
8.3 Physical Examination
8.4 Laboratory Tests
8.5 Specialized Diagnostic Tests
8.5.1 Nocturnal Penile Tumescence (NPT) and Rigidity Test
8.5.2 Intracavernous Injection Test
8.5.3 Duplex Ultrasound of Penis
8.5.4 Arteriography and Dynamic Infusion Cavernosometry
8.5.5 Psychiatric Assessment
8.6 Treatment
8.6.1 Initial Treatment Approach
8.6.2 Treatment Options for ED

9 Pipeline Landscape
9.1 Overview
9.2 Key Investigational Drugs/Devices
9.3 Dormant/Terminated/Withdrawn Drug Candidates
9.4 Product Profile: Pheonix
9.4.1 Overview
9.4.2 Product Profile
9.4.3 Future Outlook
9.5 Product Profile: MED2002 (Glyceryl Trinitrate (GTN))
9.5.1 Overview
9.5.2 Product Profile
9.5.3 Future Outlook

10 Marketed Products Landscape
10.1 Overview
10.2 Product Approval Timeline
10.3 Comparative Analysis of ED Pharmaceuticals
10.3.1 Comparative Analysis of PDE5 inhibitors
10.4 Comparative Analysis Of ED Devices

11 Unmet needs In Erectile Dysfunction Market

12 Market Dynamics
12.1 Market Growth Enablers
12.1.1 Increase in Incidence of ED and Other Related Chronic Diseases
12.1.2 Increase in Adoption of Advanced Alternative Modalities
12.1.3 Increase in Disease Awareness
12.1.4 YOY Impact of Market Enablers
12.2 Market Growth Restraints
12.2.1 Low Treatment Seeking Pool
12.2.2 Key Patent Expiries and Increased Low-cost Generics Medicines
12.2.3 Risk of Counterfeit Versions
12.2.4 YOY Impact of Market Restraints
12.3 Market Opportunities & Trends
12.3.1 Technological Advances in ED Treatment Modalities
12.3.2 Advances in ED Drug Formulations
12.3.3 Increase in Strategic Agreements and Consolidations
12.3.4 YOY Impact of Trends and Opportunities

13 Global Erectile Dysfunction Market
13.1 market Overview
13.2 Market Size & Forecast

14 Erectile Dysfunction Market- by Therapy Type
14.1 Segment Overview

15 Drug Therapy Market
15.1 Overview
15.2 Oral Therapies
15.2.1 Market Size & Forecast
15.3 Topical Therapies
15.3.1 Market Size & Forecast
15.4 Injectable and Intraurethral Suppositories
15.4.1 Market Size & Forecast

16 Device Therapy Market
16.1 Overview
16.2 Penile Implants
16.2.1 Market Size & Forecast
16.3 Vacuum Therapy Devices
16.3.1 Market Size & Forecast
16.4 Others Erectile Dysfunction Devices
16.4.1 Market Size & Forecast

17 Erectile Dysfunction Market - Geography
17.1 Market Overview

18 North America: Erectile Dysfunction Market
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Erectile Dysfunction Drugs Market
18.3.1 Market Size & Forecast
18.4 Erectile Dysfunction Devices Market
18.4.1 Market Size & Forecast
18.5 Key Countries
18.5.1 US: Market Size & Forecast
18.5.2 Canada: Market Size & Forecast

19 Europe: Erectile Dysfunction Market
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Erectile Dysfunction Drugs Market
19.3.1 Market Size & Forecast
19.4 Erectile Dysfunction Devices Market
19.4.1 Market Size & Forecast
19.5 Key Countries
19.5.1 Germany: Market Size & Forecast
19.5.2 UK: Market Size & Forecast
19.5.3 France: Market Size & Forecast
19.5.4 Italy: Market Size & Forecast
19.5.5 Spain: Market Size & Forecast

20 APAC: Erectile Dysfunction Market
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Erectile Dysfunction Drugs Market
20.3.1 Market Size & Forecast
20.4 Erectile Dysfunction Devices Market
20.4.1 Market Size & Forecast
20.5 Key Countries
20.5.1 Japan: Market Size & Forecast
20.5.2 China: Market Size & Forecast
20.5.3 India: Market Size & Forecast
20.5.4 Australia: Market Size & Forecast

21 Latin America: Erectile Dysfunction Market
21.1 Market Overview
21.2 Market Size & Forecast
21.3 Erectile Dysfunction Drugs Market
21.3.1 Market Size & Forecast
21.4 Erectile Dysfunction Devices Market
21.4.1 Market Size & Forecast
21.5 Key Countries
21.5.1 Brazil: Market Size & Forecast
21.5.2 Mexico: Market Size & Forecast

22 MEA: Erectile Dysfunction Market
22.1 Market Overview
22.2 Market Size & Forecast
22.3 Erectile Dysfunction Drugs Market
22.3.1 Market Size & Forecast
22.4 Erectile Dysfunction Devices Market
22.4.1 Market Size & Forecast

23 Competitive Landscape
23.1 Competitive Overview: Erectile Dysfunction Drugs Segment
23.2 Competitive Overview: Erectile Dysfunction Devices Segment
23.3 Key News
23.4 Strategic Recommendations for Market Participants

24 Key Company Profiles
24.1 Bayer AG
24.1.1 Key Financial Highlights
24.1.2 Strength Assessment
24.1.3 Strategy Assessment
24.1.4 Opportunity Assessment
24.2 ELI LILLY and Company
24.2.1 Key Financial Highlights
24.2.2 Strength Assessment
24.2.3 Strategy Assessment
24.2.4 Opportunity Assessment
24.3 VIVUS Inc.
24.3.1 Key Financial Information
24.3.2 Strength Assessment
24.3.3 Strategy Assessment
24.3.4 Opportunity Assessment
24.4 Pfizer
24.4.1 Key Financial Highlights
24.4.2 Strength Assessment
24.4.3 Strategy Assessment
24.4.4 Opportunity Assessment
24.5 Boston Scientific Corp.
24.5.1 Key Financial Highlights
24.5.2 Strength Assessment
24.5.3 Strategy Assessment
24.5.4 Opportunity Assessment
24.6 ColoPlast A/S
24.6.1 Strength Assessment
24.6.2 Strategy Assessment
24.6.3 Opportunity Assessment

25 Other Prominent Companies
25.1 Apricus Biosciences INC.
25.1.1 Strength Assessment
25.1.2 Strategy Assessment
25.1.3 Opportunity Assessment
25.2 Endo International plc
25.2.1 Strength Assessment
25.2.2 Strategy Assessment
25.2.3 Opportunity Assessment
25.3 Futura MedICAL plc
25.3.1 Strength Assessment
25.3.2 Strategy Assessment
25.3.3 Opportunity Assessment
25.4 Promedon
25.4.1 Strength Assessment
25.4.2 Strategy Assessment
25.4.3 Opportunity Assessment
25.5 Teva Pharmaceuticals Ltd.
25.5.1 Strength Assessment
25.5.2 Strategy Assessment
25.5.3 Opportunity Assessment
25.6 Zephyr Surgical Implants (ZSI)
25.6.1 Strength Assessment
25.6.2 Strategy Assessment
25.6.3 Opportunity Assessment
25.7 Augusta Medical Systems LLC
25.7.1 Strength Assessment
25.7.2 Strategy Assessment
25.7.3 Opportunity Assessment
25.8 Post-T-Vac Medical
25.8.1 Strength Assessment
25.8.2 Strategy Assessment
25.8.3 Opportunity Assessment
25.9 Bonro Medical
25.9.1 Strength Assessment
25.9.2 Strategy Assessment
25.9.3 Opportunity Assessment
25.10 Cristalia Produtos Quimicos Farmaceuticos Ltda
25.10.1 Strength Assessment
25.10.2 Strategy Assessment
25.10.3 Opportunity Assessment
25.11 SK Chemicals
25.11.1 Strength Assessment
25.11.2 Strategy Assessment
25.11.3 Opportunity Assessment

26 Report Summary
26.1 Qualitative Summary of Global ED Market
26.2 Quantitative Summary of Erectile Dysfunction Market

27 Appendix
27.1 List of Abbreviations

List of Exhibits
Exhibit 1 Segmentation of Global ED Market
Exhibit 2 Market Size Calculation Approach 2017
Exhibit 3 Schematic Representation of Penile Erection
Exhibit 4 Snapshot of ED Pathophysiology
Exhibit 5 Common Signs and Symptoms of Erectile Dysfunction
Exhibit 6 International Society of Impotence Research's ED Classification
Exhibit 7 Distinguishing Features of ED Sub-types
Exhibit 8 Common Causes of ED
Exhibit 9 Percent of ED Cases Caused due to Specific Conditions
Exhibit 10 ED Global Prevalence Projection 1995-2025 (Million)
Exhibit 11 Basic Diagnostic Work-up in Patients with ED
Exhibit 12 ED Treatment Algorithm
Exhibit 13 ED Product Approval Timeline
Exhibit 14 Limitations of Alternative ED Therapies
Exhibit 15 Increase in Global Diabetes Prevalence by Region 2015-2040 (Million)
Exhibit 16 ED Prevalence by Region 1995 and 2025 (Million)
Exhibit 17 Major Factors Restricting ED Treatment
Exhibit 18 Global ED Market 2017-2023 ($ million)
Exhibit 19 Global ED Market by Therapy Type
Exhibit 20 Percentage of ED Market Share by Therapy Type (2017, 2020, and 2023)
Exhibit 21 Global ED Market by Therapy Type ($ million)
Exhibit 22 Global ED Market Lucrativeness by Therapy Type
Exhibit 23 Global ED Drugs Market by Drug Type 2017-2023 ($ million)
Exhibit 24 Percentage Shares of Types of ED Drug Therapies (2017-2023)
Exhibit 25 Global Revenue of Blockbuster ED Drugs (2012-2016) ($ million)
Exhibit 26 Key Advantages and Disadvantages of Oral ED Treatments
Exhibit 27 Global Oral ED Drug Therapy Market Size and Forecast 2017-2023 ($ million)
Exhibit 28 Key Advantages and Disadvantages of Topical ED Treatments
Exhibit 29 Global Topical ED Drug Therapy Market Size and Forecast 2017-2023 ($ million)
Exhibit 30 Key Advantages and Disadvantages of Penile Injection Treatments
Exhibit 31 Key Advantages and Disadvantages of Intraurethral Suppositories
Exhibit 32 Global ED Injection and Suppository Drug Therapy Market ($ million) 2017-2023
Exhibit 33 Global ED Devices Market by Drug Type 2017-2023 ($ million)
Exhibit 34 Percentage Shares of Types of Drug Therapies 2017-2023
Exhibit 35 Key Conventionally Available Penile Implants
Exhibit 36 Key Factors Considered for Penile Implant Surgery
Exhibit 37 Key Advantages and Drawbacks of Penile Implants
Exhibit 38 Global ED Penile Implants Market Size and Forecast 2017-2023 ($ million)
Exhibit 39 Key Advantages and Drawbacks of Vacuum Constriction Devices
Exhibit 40 Global ED Vacuum Therapy Device Market Size and Forecast 2017-2023 ($ million)
Exhibit 41 Global Other ED Device Market Size and Forecast 2017-2023 ($ million)
Exhibit 42 Global ED Market by Geography
Exhibit 43 Global ED Market by Geography ($ million)
Exhibit 44 Market Revenue Growth Rates Comparison by Geography
Exhibit 45 Global ED Market Lucrativeness by Geography 2023
Exhibit 46 ED Market in North America by Country 2017
Exhibit 47 Prevalence of ED in North America
Exhibit 48 ED Market in North America 2017-2023 ($ million)
Exhibit 49 ED Drugs Market in North America 2017-2023 ($ million)
Exhibit 50 ED Devices Market in North America 2017-2023 ($ million)
Exhibit 51 ED Market in US 2017-2023 ($ million)
Exhibit 52 ED Market in Canada 2017-2023 ($ million)
Exhibit 53 ED Market in Europe by Country 2017
Exhibit 54 Prevalence Trend of Prostate Cancer Holding High Associated Risk for ED Incidence in Europe 2012-2020 (thousand)
Exhibit 55 ED Market in Europe 2017-2023 ($ million)
Exhibit 56 ED Drugs Market in Europe 2017-2023 ($ million)
Exhibit 57 ED Devices Market in Europe 2017-2023 ($ million)
Exhibit 58 Open and Transurethral Proctectomy Surgeries in Germany 2012-2015 (in ‘000’s)
Exhibit 59 ED Market in Germany 2017-2023 ($ million)
Exhibit 60 ED Market in UK 2017-2023 ($ million)
Exhibit 61 ED Market in France 2017-2023 ($ million)
Exhibit 62 ED Market in Italy 2017-2023 ($ million)
Exhibit 63 ED Market in Spain 2017-2023 ($ million)
Exhibit 64 ED Market in APAC 2017-2023 ($ million)
Exhibit 65 ED Drugs Market in APAC 2017-2023 ($ million)
Exhibit 66 ED Devices Market in APAC 2017-2023 ($ million)
Exhibit 67 ED Market in Japan 2017-2023 ($ million)
Exhibit 68 ED Market in China 2017-2023 ($ million)
Exhibit 69 ED Market in India 2017-2023 ($ million)
Exhibit 70 ED Market in Australia 2017-2023 ($ million)
Exhibit 71 ED Market in Latin America 2017-2023 ($ million)
Exhibit 72 ED Drugs Market in Latin America 2017-2023 ($ million)
Exhibit 73 ED Devices Market in Latin America 2017-2023 ($ million)
Exhibit 74 ED Market in Brazil 2017-2023 ($ million)
Exhibit 75 ED Market in Mexico 2017-2023 ($ million)
Exhibit 76 ED Market in MEA 2017-2023 ($ million)
Exhibit 77 ED Drugs Market in MEA 2017-2023 ($ million)
Exhibit 78 ED Devices Market in MEA 2017-2023 ($ million)
Exhibit 79 Leading ED Drug Vendors
Exhibit 80 Leading ED Drug Vendors
Exhibit 81 Key Vendors in ED Device Market by Product Type
Exhibit 82 Strategic Success Factors of Companies in Global ED Market
Exhibit 83 Bayer: Key Financial Highlights 2015-2016 ($ billion)
Exhibit 84 Bayer: Key Financial Highlights and Revenue by Region 2015-2016 ($ Billion)
Exhibit 85 Eli Lilly: Key Financial Highlights ($ billion)
Exhibit 86 Eli Lilly: Key Financial Highlights Revenue by Therapeutic Area 2016
Exhibit 87 Vivus: Key Financial Highlights Revenue ($ million)
Exhibit 88 Pfizer: Key Financial Highlights ($ billion)
Exhibit 89 Boston Scientific: Key Financial Highlights Revenue by Business Segment (%) (2016)
Exhibit 90 Boston Scientific: Key Financial Highlights

List of Tables
Table 1 Key Geographies Definition
Table 2 Key Caveats
Table 3 Currency Conversion 2013-2017
Table 4 Common Causes of ED by Sub-Type
Table 5 Key Investigational Drugs/Devices for Treatment of ED
Table 6 Terminated/Withdrawn Drug Candidates
Table 7 PheoniX Product Profile
Table 8 MED2002 Product Profile
Table 9 Comparative analysis of key PDE5 inhibitors
Table 10 Comparative Analysis of Key ED Devices' Functionalities
Table 11 Limitations and Adverse Events Associated with PDE5 Inhibitors
Table 12 YOY Impact of Market Enablers 2017-2023
Table 13 Patent Expiry Timeline of Key ED Drugs
Table 14 YOY Impact of Market Restraints 2017-2023
Table 15 YOY Impact of Trends and Opportunities 2017-2023
Table 16 Global ED Market by Therapy Type 2017-2023 ($ million)
Table 17 Global ED Drugs Market by Therapy Type 2017-2023 ($ million)
Table 18 Patent Loss Timeline for Viagra, Cialis, and Levitra
Table 19 Global ED Devices Market by Therapy Type 2017-2023 ($ million)
Table 20 Key Commercial Penile Implants by Type
Table 21 Key Commercial Vacuum Constriction Devices
Table 22 Global ED Market by Geography 2017-2023 ($ million)
Table 23 ED Drugs Product Portfolio of Other Prominent Vendors
Table 24 Qualitative Summary of Global ED Market
Table 25 Quantitative Summary of Global ED Market by Geography ($ million)
Table 26 Quantitative Summary of Global ED Market by Geography (Revenue %)
Table 27 Quantitative Summary of Global ED Market by Therapy Type ($ million)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • SK Chemicals
  • Cristalia Produtos Quimicos Farmaceuticos Ltd
  • Bonro Medical
  • Post-T-Vac Medical
  • Augusta Medical Systems LLC (Augusta Medical)
  • Zephyr Surgical Implants (ZSI)
  • Teva Pharmaceutical Industries Limited (Teva)
  • Premedon
  • Futura Medical
  • Endo International plc
  • Apricus Biosciences
  • Coloplast A/S
  • Boston Scientific Corp
  • VIVUS Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Pfizer
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll